跳至主要内容
临床试验/NCT00943345
NCT00943345Unknown早期 1 期

Dubbelblind Crossover Study for Validation of New Tests for Gastrointestinal (GI) Permeability

Maastricht University Medical Center1 个研究点 分布在 1 个国家目标入组 34 人开始时间: 2009年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
入组人数
34
试验地点
1
主要终点
Comparison of permeability tests (new versus golden standard dual sugar test)

研究概览

简要总结

Introduction: The primary function of the gastrointestinal (GI) wall is digestion and absorption of nutrients that are important for growth and development. The second important function of the GI wall is forming an effective barrier to prevent penetration of potentially harmful components from the inside of the gut (lumen), via the GI wall, into the body.

A compromised barrier function may play an important role in the development of a range of inflammatory GI diseases such as coeliac disease, Inflammatory Bowel Disease (IBD), food allergy, but also in the pathophysiology of postoperative complications. It is important and clinically relevant to have reliable GI permeability tests, however the existing test leave room for improvement.

Rationale/aim: Three new tests are developed to assess gastrointestinal permeability in both normal controls with and without raised permeability, and in patients with coeliac disease. In the current study these new permeability tests will be evaluated and compared with the golden standard permeability test, the dual sugar test.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Diagnostic
盲法
Triple (Participant, Care Provider, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • healthy controls, female/male, 18-75 years of age, OR:
  • coeliac disease without taking medicine, female/male, 18-75 years of age

排除标准

  • cardiac and/or vascular disease
  • chronic obstructive pulmonary disease (COPD)
  • rheumatic arthritis (RA)
  • Inflammatory bowel disease(IBD); Crohn's colitis or colitis ulcerosa
  • Irritable bowel syndrome (IBS)
  • Inflammatory systemic disease
  • Obesity (Body Mass Index ≥ 30 kg/m²)
  • Diabetes Mellitus
  • Thyroid disease
  • Kidney disease
  • Substance abuse (alcohol, drug, cocain, opioids, and others)
  • Use of drugs
  • Operations to the GI system, apart from appendectomy
  • Allergy to eggs or milk
  • Hypersensitivity to any of the following: lactulose, l-rhamnose, sucrose, sucralose of erythritol
  • Acute porphyria or phenylketonuria (PKU)
  • Pregnancy

研究组 & 干预措施

GS dual sugar permeability test

Active Comparator

Golden standard GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).

Coeliac patients will only have 1 test to assess basal GI permeability.

干预措施: indometacin (Drug)

Multi sugar test

Other

New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).

Coeliac patients will only have 1 test to assess basal GI permeability.

干预措施: indometacin (Drug)

Protein test

Other

New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).

Coeliac patients will only have 1 test to assess basal GI permeability.

干预措施: indometacin (Drug)

PEG test

Other

New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).

Coeliac patients will only have 1 test to assess basal GI permeability.

干预措施: indometacin (Drug)

结局指标

主要结局

Comparison of permeability tests (new versus golden standard dual sugar test)

时间窗: 24 hours

次要结局

  • GI permeability(24 hours)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Kim van Wijck

MD, PhD student

Maastricht University Medical Center

研究点 (1)

Loading locations...

相似试验

Validation of New Tests for Gastrointestinal (GI)... | 临床试验